Subscribe
pills-istock-525984851
sprng23 / iStockphoto.com
9 May 2018Americas

Lannett gains generic product portfolio from Endo subsidiary

Generic drug manufacturer Lannett has acquired the product portfolio of an Endo International subsidiary.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Endo resolves FTC allegations over Lidoderm and Opana ER
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.
Americas
FTC antitrust charges against Impax dismissed
25 May 2018   A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Endo resolves FTC allegations over Lidoderm and Opana ER
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.
Americas
FTC antitrust charges against Impax dismissed
25 May 2018   A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.

More on this story

Americas
Endo resolves FTC allegations over Lidoderm and Opana ER
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.
Americas
FTC antitrust charges against Impax dismissed
25 May 2018   A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?